Roullet B, Labadie M, Taper H, Lans M, Economidou-Karaoglou A, Dewez B, Roberfroid M, Berdah J F, Bachellerie-Rhein B, Clavere P
Service de radiothérapie et cancérologie, CHRU Dupuytren, Limoges, France.
Bull Cancer. 1990;77(7):675-80.
Variations in serum alkaline DNase activity before and repeatedly after standardized chemotherapy were examined in patients with head and neck carcinomas. The enzyme activity was measured by way of a modified spectrophotometric method. No variations of such activity observed in patients without therapeutic response or with minor response could be considered as a marker of primary or acquired resistance to chemotherapy. Distinct variations in serum alkaline DNase activity (a steep decrease after therapy followed a few weeks later by a regain of values higher than the initial value) correspond to complete or partial positive responses. Such observations of the variations in enzyme activity in relation to individual initial values measured before therapy could be considered as a reliable prognostic test for the therapy of many head and neck carcinomas.
对头颈部癌患者标准化化疗前后及多次化疗后的血清碱性脱氧核糖核酸酶（DNase）活性变化进行了检测。采用改良分光光度法测定酶活性。在无治疗反应或轻微反应的患者中观察到的这种活性变化，不能被视为对化疗原发性或获得性耐药的标志物。血清碱性DNase活性的明显变化（治疗后急剧下降，几周后恢复到高于初始值的值）对应于完全或部分阳性反应。这种关于酶活性相对于治疗前测量的个体初始值变化的观察结果，可被视为许多头颈部癌治疗的可靠预后检测方法。
